| pubmed-article:11328693 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11328693 | lifeskim:mentions | umls-concept:C0002395 | lld:lifeskim |
| pubmed-article:11328693 | lifeskim:mentions | umls-concept:C0011923 | lld:lifeskim |
| pubmed-article:11328693 | lifeskim:mentions | umls-concept:C0080103 | lld:lifeskim |
| pubmed-article:11328693 | lifeskim:mentions | umls-concept:C0228174 | lld:lifeskim |
| pubmed-article:11328693 | lifeskim:mentions | umls-concept:C0205147 | lld:lifeskim |
| pubmed-article:11328693 | lifeskim:mentions | umls-concept:C0596620 | lld:lifeskim |
| pubmed-article:11328693 | pubmed:issue | 3-4 | lld:pubmed |
| pubmed-article:11328693 | pubmed:dateCreated | 2001-4-30 | lld:pubmed |
| pubmed-article:11328693 | pubmed:abstractText | 1 H Magnetic resonance spectroscopic imaging (MRSI) and positron emission tomography (PET) of (18) F-2-fluoro-2-deoxy-D-glucose (FDG) were performed in 18 patients with probable Alzheimer's disease (AD) and 3 normal controls. We measured the distribution and relative signal intensities of N-acetyl aspartate (NAA; a presumed neuronal marker), choline residues (Cho) representing cellular membrane compounds and of creatine-containing metabolites (Cr), and correlated these to regional cerebral glucose metabolism (rCMRGI) after coregistration of both imaging-techniques. The pattern of choline was significantly different between AD and normals (p < 0.01). RCMRGI was significantly related to Cho/Cr (r=-0.21, p<.05) and NAA/Cho quotients (r=0.35, p<.001). Our results suggest that in AD reduced neuronal energy performance and membrane abnormalities contribute to metabolic deterioration. | lld:pubmed |
| pubmed-article:11328693 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11328693 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11328693 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11328693 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11328693 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11328693 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11328693 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11328693 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11328693 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:11328693 | pubmed:issn | 0020-7454 | lld:pubmed |
| pubmed-article:11328693 | pubmed:author | pubmed-author:HeissW DWD | lld:pubmed |
| pubmed-article:11328693 | pubmed:author | pubmed-author:KesslerJJ | lld:pubmed |
| pubmed-article:11328693 | pubmed:author | pubmed-author:PietrzykUU | lld:pubmed |
| pubmed-article:11328693 | pubmed:author | pubmed-author:HeindelWW | lld:pubmed |
| pubmed-article:11328693 | pubmed:author | pubmed-author:MielkeRR | lld:pubmed |
| pubmed-article:11328693 | pubmed:author | pubmed-author:KugelHH | lld:pubmed |
| pubmed-article:11328693 | pubmed:author | pubmed-author:SchopphoffH... | lld:pubmed |
| pubmed-article:11328693 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11328693 | pubmed:volume | 107 | lld:pubmed |
| pubmed-article:11328693 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11328693 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11328693 | pubmed:pagination | 233-45 | lld:pubmed |
| pubmed-article:11328693 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:11328693 | pubmed:meshHeading | pubmed-meshheading:11328693... | lld:pubmed |
| pubmed-article:11328693 | pubmed:meshHeading | pubmed-meshheading:11328693... | lld:pubmed |
| pubmed-article:11328693 | pubmed:meshHeading | pubmed-meshheading:11328693... | lld:pubmed |
| pubmed-article:11328693 | pubmed:meshHeading | pubmed-meshheading:11328693... | lld:pubmed |
| pubmed-article:11328693 | pubmed:meshHeading | pubmed-meshheading:11328693... | lld:pubmed |
| pubmed-article:11328693 | pubmed:meshHeading | pubmed-meshheading:11328693... | lld:pubmed |
| pubmed-article:11328693 | pubmed:meshHeading | pubmed-meshheading:11328693... | lld:pubmed |
| pubmed-article:11328693 | pubmed:meshHeading | pubmed-meshheading:11328693... | lld:pubmed |
| pubmed-article:11328693 | pubmed:meshHeading | pubmed-meshheading:11328693... | lld:pubmed |
| pubmed-article:11328693 | pubmed:meshHeading | pubmed-meshheading:11328693... | lld:pubmed |
| pubmed-article:11328693 | pubmed:meshHeading | pubmed-meshheading:11328693... | lld:pubmed |
| pubmed-article:11328693 | pubmed:meshHeading | pubmed-meshheading:11328693... | lld:pubmed |
| pubmed-article:11328693 | pubmed:meshHeading | pubmed-meshheading:11328693... | lld:pubmed |
| pubmed-article:11328693 | pubmed:year | 2001 | lld:pubmed |
| pubmed-article:11328693 | pubmed:articleTitle | Relation between 1H MR spectroscopic imaging and regional cerebral glucose metabolism in Alzheimer's disease. | lld:pubmed |
| pubmed-article:11328693 | pubmed:affiliation | Max-Planck Institute for Neurological Research, Gleueler Str. 50, D-50931 Köln, Germany. ruediger.mielke@pet.mpin-koeln.mpg.de | lld:pubmed |
| pubmed-article:11328693 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11328693 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11328693 | lld:pubmed |
